Samjin Pharmaceutical has announced the launch of 'Samjin Lorazepam Injection,' a medication classified as an essential and anti-withdrawal drug, ensuring a stable supply amid concerns over supply disruptions. The company has completed the necessary approvals for changing manufacturers and establishing a direct production system.
On July 1, Samjin Pharmaceutical revealed that the Samjin Lorazepam Injection is an anxiolytic used for preoperative sedation, pediatric seizures, and status epilepticus. It contains the same active ingredient and formulation as the previously supplied 'Ativan (Lorazepam)'.
The Lorazepam injection is recognized as an essential medicine for acute anxiety relief, emergency sedation, and seizure control, particularly valued in emergency situations involving pediatric seizures where alternatives are limited.
To ensure a stable supply of this injection, Samjin Pharmaceutical has been in discussions with relevant agencies, including the Ministry of Health and Welfare, the Food and Drug Administration, the Health Insurance Review and Assessment Service, and the National Health Insurance Service. The company has obtained approval for changing manufacturers and has established its own production and supply system, completing the entire process from licensing to in-house production.
The company has a history of consistently producing and supplying essential and anti-withdrawal medications. This includes the only domestic injection used for patients in status epilepticus, 'Samjin Diazepam,' as well as treatments for aneurysmal subarachnoid hemorrhage like 'Samjin Nimodipine,' and essential antibiotics such as 'Tiramox,' 'Jitin,' 'Hulgram,' and 'Hanomycin,' among others, which are maintained in either sole or limited supply.
Kim Sang-jin, CEO of Samjin Pharmaceutical, stated, "It is the fundamental responsibility of a pharmaceutical company to ensure the stable supply of essential medicines. We will continue to collaborate with health authorities to provide the necessary medications in the healthcare field."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.